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The effect of the implementation of the Dutch breast cancer screening programme during 1990–1997 on the incidence rates of
breast cancer, particularly advanced breast cancer, was analysed according to stage at diagnosis in seven regions, where no screening
took place before 1990. The Netherlands Cancer Registry provided detailed data on breast cancer incidence in 1989–1997 by
tumour stage, age and region. Annual age-adjusted incidence rates of all breast cancers and advanced cancers, defined as large
tumours T2þ with lymph node and/or distant metastases, were compared with rates in 1989. In general, breast cancer incidence
rose strongly in the early 1990s, especially in the age category 50–69 years (estimated annual percentage change (EAPC) 4.25; 95%
CI 1.70, 6.86). The increase was mainly due to the increase in small T1 cancers and ductal carcinoma in situ. However, in women aged
50–69, advanced cancer incidence rates showed a significant decline by 12.1% in 1997 compared with 1989 (EAPC –2.14, 95% CI
 3.47,  0.80), followed by a breast cancer mortality reduction of similar size after approximately 2 years. We confirm that breast
cancer screening initially leads to a temporary strong increase in the breast cancer incidence, which is followed by a significant
decrease in advanced diseases in the women invited for screening. It is evident that breast cancer screening contributes to a reduction
in advanced breast cancers and breast cancer mortality.
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Large-scale early detection of breast cancer leads to an increase in
newly diagnosed cases and a shift of breast cancer stages towards
higher proportions of less severe tumours. The effects of breast
cancer screening on the overall breast cancer incidence depend on
the characteristics of the screening programme such as the
targeted age range, the duration of implementation, the extent of
coverage and attendance, the screening interval and the pro-
gramme performance. A decrease in advanced disease stages is an
important predictor of the potential breast cancer mortality
reduction by mammography screening (Day et al, 1989).
Population-based mammography screening started in the mid-
1970s in two Dutch regions in and around the cities of Utrecht and
Nijmegen (‘old’ regions). From 1989 to 1997, nation-wide breast
cancer screening was implemented in The Netherlands for all
women aged 50–69 years. Early outcomes of the nation-wide
programme, such as attendance rate, breast cancer detection and
tumour stage distribution of screen-detected breast cancers, were
largely in line with the expectations that were based on a cost-
effectiveness analysis (de Koning et al, 1995; Fracheboud et al,
2001). During the 1990s, Netherlands Cancer Registry (NCR) data
showed increases in breast cancer incidence and changes in stage
distribution, particularly in the age category targeted for screening
(van Dijck et al, 2000). However, data from the registry cannot
distinguish screened from nonscreened women.
In this study, we describe stage-specific trends in the breast
cancer incidence 1989–1997 during the implementation of the
nation-wide breast cancer screening programme in The Nether-
lands. As we observed a significant decrease in breast cancer
mortality within the population targeted for screening as of 1997
(Otto et al, 2003), we assumed a decline in advanced disease stages
as well. For this reason, we focused our analyses on trends in
advanced tumour stages in the seven regions that started screening
activities after 1990 (‘new’ regions).
MATERIAL AND METHODS
Setting
The nation-wide breast cancer screening programme for women
aged 50–69 years was gradually implemented in The Netherlands
during 1989–1997. Every 2 years, eligible women get a personal
invitation letter with a fixed appointment for a screen examination
in one of the mostly mobile screening units. Over 75% of the
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linvited women attend the programme and more than 90% of the
attendees reattend in the following round. Experimental, non-
randomised breast cancer screening started in the mid-1970s in the
city of Utrecht (central region) and its environs, and in the city of
Nijmegen (eastern region). The pilot programmes were gradually
integrated in the national programme around 1989. In 1990, three
other regions started screening activities, followed by the
remaining four regions in 1991. Up to 1994, the majority of screen
examinations were initial screens, but since 1995 subsequent
screens have been carried out predominantly. The number of
screen examinations increased from 1300 per 100000 women aged
50–69 in 1990 to more than 35000 per 100000 in 1997.
The first regional cancer registry was established in the 1950s in
the southeast of The Netherlands. Only in the 1980s, cancer
registries were launched in the other eight regions. In 1989,
coverage was nation-wide, so that the regional registries could be
brought together to a national database, the Netherlands Cancer
Registry (NCR, 1992). Cancer recording is based on notifications of
malign pathology by the computerised national histopathological
database (PALGA). The records are complemented with clinical
information by the regional Comprehensive Cancer Centres and
checked for missing cases by comparing them with the national
registry of outpatient and in-patient diagnoses (LMR). The
completeness of case ascertainment of the NCR is higher than
95% (Visser et al, 2003); this percentage will be still higher for
breast cancer, because histological or cytological material is
available for nearly all cases. Tumour characteristics are registered
according to the international guidelines for classification of stage
(TNM, International Union Against Cancer (UICC)) and topo-
graphy and morphology (International Classification of Diseases
for Oncology (ICD-O)). The classification is primarily based on
histopathological TNM information; in case of unknown pN (¼X)
clinical information cN is used. Usually, it takes 3 years to
complete and publish the data on the cancer incidence of a certain
year.
Method
The National Evaluation Team for Breast cancer screening in The
Netherlands (NETB) annually collects regional aggregated data on
the screening results, including attendance, referral recommenda-
tions, screen-detected breast cancers and stage distribution. Files
of regional screening records are linked to the corresponding
regional cancer registry database to identify interval cancers. These
data are also provided to the NETB, which analyses trends in
incidence and therapy of screen-detected cancers, interval cancers
and breast cancers in nonscreened women.
In 2001, the NCR provided data on population, breast cancer
incidence, tumour size, positive or negative lymph node stage and
distant metastases by calendar year 1989–1997 and 5-year age
groups for the nine cancer registry regions separately. These
regions largely correspond to the nine breast cancer screening
regions in The Netherlands. The data include ductal carcinoma in
situ, but not lobular carcinoma in situ, which is regarded a benign
lesion. To be able to study the effect of introducing a screening
programme in a previously unscreened population, the NCR
data were subdivided into two ‘old’ regions (the central and
eastern regions where the pilot programmes took place) and into
seven ‘new’ regions that did not start screening activities until
1990.
For the national evaluation, the age at screening and of breast
cancer incidence is defined by birth year; that is, during a certain
year, the woman is considered to keep the age she had on January
1 of the same year. For this reason, women will be invited and
screened for the first time in the year when they become 50 years
old, thus having the evaluation age of 49.
As we did not have detailed information on the lymph node
status, we did not use UICC TNM stages, but grouped invasive
breast cancers into six categories: (1) small tumours T1 (up to
20mm in size) without metastases (T1N0); (2) small tumours T1
with lymph node or distant metastases (T1Nþ/M1); (3) small
tumours T1 with unknown lymph node status (T1Nx); (4) large
cancers T2þ (T2: 20–50mm in size, T3: 450mm in size and T4)
without metastases (T2þN0); (5) large cancers T2þ with lymph
node or distant metastases (T2þNþ/M1) and (6) large cancers
T2þ with unknown lymph node status (T2þNx). We defined
category (5) T2þNþ/M1 as ‘advanced cancers’ in our study. The
proportion of Tx and unclassified cancers varied between 2.1 and
3.2% of the annual breast cancer total. The same variation was
observed within 5-year age groups, except the oldest age group
(479 years) in which the proportion of Tx and unclassified
cancers was approximately 5%.
All breast cancer incidence rates were calculated per 100000
women by dividing the number of new breast cancer cases in a
certain year by the mid-year female population (the average of the
population at January 1 of that year and the population at January
1 of the following year). As the NCR did not supply population
figures of January 1, 1998, we estimated it for the individual cancer
registry regions by multiplying the 1997 regional age-specific
population numbers by the age-specific percent change between
1997 and 1998 of the national population. All rates were age-
adjusted by means of direct standardisation using the European
Standard Population as reference.
Assuming a constant change of incidence rates over time, we
estimated trends using the estimated annual percentage change
(EAPC) by fitting a regression line to the natural logarithm of the
incidence rates as dependent variable, and testing the slope by
the t-distribution (number of degree of freedom equals the
number of calendar year minus 2). The significance level of
differences in advanced cancer incidence rates was estimated by
means of the expected standard deviation of the difference in
incidence rate of a certain year and age group compared with 1989,
according to the method that we used for assessing changes in
breast cancer mortality (van den Akker-van Marle et al, 1999; Otto
et al, 2003).
RESULTS
Table 1 gives the age-adjusted combined invasive and in situ breast
cancer incidence rates in 1989–1997 and the percent change
compared with 1989 by different age categories. In the total Dutch
female population, incidence rates increased in all age groups.
They reached a maximum in 1993–1994 and then slightly declined
but still remained higher than the initial level. The overall
incidence was highest in 1994 (25.9% increase compared to
1989). In women aged 50–69, the incidence rate reached a
maximum in 1993 (39.2% increase compared to 1989). In younger
women, the increase was more gradual and reached its maximum
in 1996–1997 (þ15.6% compared with 1989), whereas in older
women the increase did not exceed 12.5%.
The increase of incidence rates was more pronounced in the
‘new’ regions, especially in women aged 50–69, in whom the
incidence rate remained beyond 300 per 100000 from 1992
onwards (EAPC 4.25; 95% CI 1.70, 6.86; Table 1). These rates are
approx. 40% higher than the incidence rate in 1989 (225.8 per
100000), which can be regarded as baseline incidence in an
unscreened population in The Netherlands. In the ‘old’ regions, in
women aged 50–69, the breast cancer incidence was substantially
higher in 1989 (284.2 per 100000) and reached the highest
incidence level in 1993 with 347.3 per 100000 (increase by 22.2%).
However, there was no significant change of incidence rates over
the total period 1989–1997.
Figure 1 shows that the incidence rates of both, invasive and in
situ breast cancers, increased in all age categories in the seven
‘new’ regions, but that this increase was the strongest in women
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laged 50–69. In 1997, a quarter of all newly diagnosed invasive and
in situ breast cancers were detected by the screening programme,
and one out of eight was diagnosed in screened women during the
interval period between two screening rounds (Figure 2). In
women aged 50–69 years, half of all breast cancers were screen-
detected cancers and a quarter were symptomatic cancers in ever-
screened women.
Figure 3 shows that the increase in overall invasive breast cancer
rates (Figure 3a) was mainly caused by an increase of T1 tumours,
especially lymph node negative T1 tumours (T1N0), and
particularly in the age category 50–69 (Figure 3c). In this age
category, the doubling of small lymph node negative tumours was
followed by a decline in T2þ cancers with lymph node or distant
metastases (T2þNþ/M1). In younger and older women, the
incidence rates of these cancers showed a nonsignificant slightly
increasing trend (EAPC 0.84 and 1.09% for women aged o50 and
469 years, respectively; Table 2). In women aged 50–69, after a
moderate increase by approx. 3% up to 1994, incidence rates of
advanced disease are significantly lower from 1996 onwards (EAPC
 2.14; 95% CI  3.47,  0.80; Table 2). This resulted in a decrease
by 12.1% in 1997 compared to that in 1989 (63.0 vs 71.6 per
100000). In the ‘old’ regions, the decline in this age category was
larger, with an EAPC of  5.5 (95% CI  8.52,  2.37; data not
shown).
Table 3 compares the incidence rates of advanced breast cancers
with the breast cancer mortality in The Netherlands (all nine
Table 1 Annual age-adjusted invasive and ductal in situ breast cancer rates (ESR per 100000 woman-years) in 1989–1997 and per cent change since
1989
Seven ‘new’ regions
a Two ‘old’ regions
b Netherlands (nine regions)
Breast cancer Change (1989¼0) Breast cancer Change (1989¼0) Breast cancer Change (1989¼0)
Age category N Rate % N Rate % N Rate %
o50 years
1989 1826 43.2 — 372 42.7 — 2198 43.1 —
1990 1930 44.8 3.6 386 43.8 2.5 2316 44.6 3.4
1991 2018 45.6 5.6 455 50.2 17.6 2473 46.4 7.6
1992 2057 45.3 4.8 452 48.7 13.9 2509 45.9 6.3
1993 2201 47.5 9.9 442 46.2 8.0 2643 47.2 9.6
1994 2278 48.3 11.7 473 48.3 12.9 2751 48.3 11.9
1995 2267 47.2 9.2 444 44.6 4.3 2711 46.7 8.4
1996 2375 49.2 14.0 516 51.5 20.4 2891 49.6 15.1
1997 2376 49.6 14.8 509 51.1 19.6 2885 49.9 15.6
EAPC (95% CI) 1.63 (1.47, 2.09) 1.59 ( 0.18, 3.39) 1.62 (1.05, 2.2)
50–69 years
1989 2795 225.8 — 671 284.2 — 3466 235.3 —
1990 2999 240.8 6.6 726 301.8 6.2 3725 250.7 6.5
1991 3316 265.6 17.6 743 304.3 7.1 4059 271.9 15.5
1992 3821 304.3 34.8 820 338.3 19.0 4641 309.9 31.7
1993 4059 323.6 43.3 846 347.3 22.2 4905 327.5 39.2
1994 4105 325.0 43.9 810 323.7 13.9 4915 324.8 38.0
1995 3968 312.0 38.2 746 296.4 4.3 4714 309.4 31.5
1996 4082 314.5 39.3 704 273.7  3.7 4786 307.8 30.8
1997 4160 313.0 38.6 797 300.4 5.7 4957 310.9 32.1
EAPC (95% CI) 4.25 (1.70, 6.86)  0.28 ( 2.77, 2.28) 3.45 (0.98, 5.99)
469 years
1989 2004 211.2 — 344 210.0 — 2348 211.0 —
1990 2075 208.4  1.3 458 249.2 18.7 2533 214.8 1.8
1991 2123 210.6  0.3 425 238.3 13.5 2548 214.9 1.9
1992 2268 221.5 4.9 465 235.8 12.3 2733 223.8 6.1
1993 2259 213.2 1.0 416 197.0  6.2 2675 210.7  0.2
1994 2583 240.2 13.8 453 221.8 5.6 3036 237.3 12.5
1995 2400 223.0 5.6 470 221.3 5.4 2870 222.7 5.6
1996 2489 221.0 4.6 472 228.9 9.0 2961 222.3 5.3
1997 2490 219.8 4.1 463 215.6 2.7 2953 219.1 3.9
EAPC (95% CI) 0.89 ( 0.29, 2.09)  0.60 ( 2.82, 1.68) 0.64 ( 0.43, 1.72)
All ages
1989 6625 101.3 — 1387 112.4 — 8012 103.1 —
1990 7004 106.1 4.8 1570 122.8 9.2 8574 108.8 5.5
1991 7457 112.3 10.9 1623 125.5 11.6 9080 114.5 11.1
1992 8146 121.5 20.0 1737 133.6 18.8 9883 123.5 19.8
1993 8519 126.7 25.1 1704 130.3 15.9 10223 127.3 23.5
1994 8966 130.2 28.6 1736 127.9 13.8 10702 129.8 25.9
1995 8635 124.7 23.2 1660 120.2 6.9 10295 124.0 20.2
1996 8946 127.1 25.5 1692 119.4 6.2 10638 125.8 22.1
1997 9026 126.7 25.1 1769 124.4 10.6 10795 126.3 22.5
EAPC (95% CI) 2.90 (1.40, 4.43) 0.32 ( 1.33, 2.00) 2.46 (0.98, 3.96)
aStarted screening activities in 1990 or 1991.
bScreening activities before 1989 (regions with pilot programmes). EAPC¼estimated annual percentage change.
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lregions, women aged 55–74) during the 1990s (Otto et al, 2003).
This reduction of advanced diseases precedes the observed
significant breast cancer mortality reduction of a comparable
extent by approximately 2 years.
DISCUSSION
The implementation of the nation-wide breast cancer screening
programme in The Netherlands from 1990 to 1997 coincided with
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lan obvious increase in the incidence rates of both invasive and in
situ breast cancers. This increase was strongest in women aged
50–69 years, the main target population for the programme,
especially in the early 1990s, when predominantly initial screen
examinations were carried out. The average detection rate was at
that time 6.1 per 1000 initially screened women (NETB (National
Evaluation Team for Breast cancer screening in The Netherlands),
2001). In 1995–1997, with a large majority of subsequent screen
examinations (average detection rate 3.4 per 1000 screened
women), the overall incidence fell to a lower level. It remained,
however, above the 1989 baseline. This trend is consistent with the
expected development of the breast cancer incidence that had been
predicted previously by our group (de Koning et al, 1990). We
found an estimated annual percentage change (EAPC) of 2.46 with
respect to the overall incidence including ductal carcinoma in situ.
In their last report, the NCR calculated for invasive breast cancers
only an EAPC of 1.5% (P-value 0.0009) for the period 1989–2000
(Visser et al, 2003).
The proportion of breast cancers that were diagnosed as a result
of a screen examination increased gradually during the study
period. In 1997, when the screening programme was fully
implemented in The Netherlands, one out of four breast cancers
was screen-detected and this ratio was even one out of two in
women aged 50–69 years. In this age category, another 25% of the
breast cancers were diagnosed during the screening interval after a
negative screen examination. The remaining 25% were diagnosed
in nonscreened women.
Various studies described an increase in breast cancer incidence
rates in the last two to three decades for both, situations with and
without organised mammography screening (Quinn and Allen,
1995; Chu et al, 1996; McCann et al, 1998; Kricker et al, 1999; Paci
et al, 2002; Schouten et al, 2002; Botha et al, 2003; Buiatti et al,
2003). Where organised screening has been introduced, this
increase is more marked, mainly as a result of the additional
detection of early breast cancer stages. The extent of the increase is
– besides the country-specific underlying incidence – directly
related to the intensity of the screening programme, for example,
the targeted proportion of the female population, the speed of
implementation, the screening interval, the quality of the
programme and the participation rate (Threlfall et al, 2003). In
most studies, a decline was observed after the initial screening
round had been finished. Those studies with a sufficiently long
follow-up provided valuable insight into the course of the total
breast cancer incidence during subsequent screens. In general, the
incidence remains higher than in the prescreening period, which
raises the question whether the ongoing subsequent screening
leads to overdiagnosis or whether the breast cancer risk is
increasing. It is important to realise that the initial increase does
not signify overdiagnosis, but that it is the result of the necessary
downstaging of breast cancer diagnoses, if screening will be
effective. Several authors concluded that overdiagnosis might be
limited to a few percent (Boer et al, 1994; Olsen et al, 2003; Yen
et al, 2003; Paci et al, 2004). It is likely that besides organised
screening and the general tendency towards earlier detection
(increased awareness, spontaneous mammography) other factors,
such as declining fertility rates and the widespread use of hormone
replacement therapy, contribute to the observed increase in breast
cancer incidence (Prehn et al, 2002; Beral, 2003; Coebergh, 2003; Li
et al, 2003).
The present study confirms that relatively more small lymph
node negative cancers were detected in the targeted age category
50–69 after the start of the programme. More importantly, in this
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lsame age group, the incidence rate of large cancers with lymph
node or distant metastases began to decline significantly in 1996.
In 1997, this rate was a significant 12.1% lower than that in 1989.
We defined advanced breast cancer as tumour size T2þ in
combination with positive lymph nodes and/or distant metastases.
This does not fully correspond with the TNM stages IIB–IV,
because we did not take into account node-negative T4 cancers
(stage IIIB, in total 117–184 per year), T4 cancers with unknown
lymph node findings (stage IIIB, 24–40 per year) and tumours TX
with distant metastases (stage IV, 40–56 per year). Given the fact
that we selected the worst cases of large tumours, the reduction of
advanced cancers in women aged 50–69 is strongly indicative of a
screening effect, especially since the other age categories showed
no tendency towards lower incidence rates of these cancers. We
found a similar pattern in the two ‘old’ regions, but the decrease in
advanced cancers in women aged 50–69 was much more
pronounced (EAPC  5.50; 95% CI  8.52,  2.37), resulting in a
38.7% lower rate in 1997 compared with 1989 (data not shown). If
the ‘old’ regions, where the programme was already fully
implemented in 1993–1994, predict the trend for the nation-wide
programme, then we can expect a substantial further reduction in
the advanced cancer incidence in the next years.
In the seven ‘new’ regions, the decline in advanced cancer rates
in women aged 50–69 began in the 7th year of screening activities
when approx. 85% of the targeted population had been invited at
least once. Day et al (1989) suggested a rate reduction of advanced
cancers of at least 30% 7 years after the first invitation is sent. Our
results are far from this desirable level. One of the reasons is that
the implementation of a nation-wide programme takes much
longer than that of a smaller screening trial, in the Dutch situation,
even more than 7 years. Differences in screening performance may
be another reason. As far as we know, the published reductions of
advanced cancer rates in regions with a service screening
programme have not reached 30% up to now. New South Wales
reported a 20% reduction of large (T3þ) cancers in women aged
50–69 years (Kricker et al, 1999). For the East Anglia region, the
estimated reduction of advanced stages II–IV was 7–19% after 7
years (McCann et al, 1998). In the small Dutch region Limburg,
one of the seven ‘new’ regions, the incidence of stage II–IV cancers
was reduced by an estimated 10% and 18% after 5 and 10 years
(Schouten et al, 1998, 2002). Based on NCR data, a 24% reduction
was reported for the combined stages III and IV in 1995 (van Dijck
et al, 2000). Our results are largely in line with these outcomes,
despite the somewhat different definition of advanced disease.
Assuming that women with advanced cancers will mostly die of
breast cancer, the reduction in advanced disease by screening can
be regarded as a predictor of the future breast cancer mortality
reduction. In fact, the breast cancer mortality in Dutch women
Table 2 Annual age-adjusted incidence rates (ESR) and rate difference
compared with 1989 of advanced breast cancers (T2+/N+/M1) per
100000 women in the seven ‘new’ regions
T2+/N+/M1
N Per 100000
Rate difference
compared to
1989 (95% CI)
o50 years
1989 496 11.8 —
1990 584 13.6 1.8 (0.3, 3.3)
1991 569 12.9 1.2 ( 0.3, 2.7)
1992 559 12.3 0.6 ( 0.9, 2.0)
1993 633 13.7 1.9 (0.4, 3.4)
1994 619 13.1 1.4 ( 0.1, 2.8)
1995 630 13.1 1.4 ( 0.1, 2.8)
1996 621 12.9 1.2 ( 0.3, 2.6)
1997 649 13.6 1.8 (0.3, 3.3)
EAPC 0.84 ( 0.59, 2.29)
50–69 years
1989 884 71.6 —
1990 917 73.7 2.1 ( 4.7, 8.9)
1991 914 73.6 2.0 ( 4.8, 8.8)
1992 926 74.2 2.6 ( 4.2, 9.4)
1993 920 73.7 2.1 ( 4.7, 8.8)
1994 901 71.6  0.0 ( 6.7, 6.7)
1995 815 64.6  7.0 ( 13.6, 0.5)
1996 808 62.6  9.1 ( 15.5,  2.6)
1997 833 63.0  8.6 ( 15.1,  2.2)
EAPC  2.14 ( 3.47,  0.80)
469 years
1989 572 85.3 —
1990 641 94.9 9.6 (0.3, 18.9)
1991 606 88.5 3.2 ( 14.4, 20.8)
1992 664 94.9 9.6 (0.3, 18.8)
1993 661 92.1 6.8 ( 2.3, 15.8)
1994 737 102.0 16.7 (7.3, 26.0)
1995 670 91.2 5.9 ( 3.1, 14.9)
1996 726 96.3 11.0 (1.9, 20.0)
1997 734 96.1 10.8 (1.8, 19.8)
EAPC 1.09 ( 0.31, 2.52)
EAPC: estimated annual percentage change.
Table 3 Annual age-adjusted rates (ESR) of advanced breast cancers (T2+/N+/M1) and breast cancer mortality in the Netherlands (all regions), and rate
difference compared with observed rates in 1989 (advanced cancers) and in 1986–88 (mortality), women aged 55–74 years
Advanced cancers (T2+N+/M1) Mortality
a
Per 100000 Rate difference (95% CI) Per 100000 Rate difference (95% CI)
1986–88 105.2 —
1989 93.6 — — 102.9  2.3 ( 8.6, 4.0)
1990 95.6 2.0 ( 6.1, 10.1) 107.5 2.3 ( 4.1, 8.7)
1991 94.4 0.8 ( 7.2, 8.9) 105.0  0.2 ( 6.6, 6.1)
1992 97.6 4.0 ( 4.1, 12.2) 102.1  3.2 ( 9.4, 3.1)
1993 91.5  2.0 ( 10.0, 6.0) 101.1  4.1 ( 10.3, 2.1)
1994 92.0  1.5 ( 9.5, 6.4) 103.9  1.3 ( 7.6, 4.9)
1995 80.4  13.1 ( 20.8,  5.4) 100.2  5.0 ( 11.1, 1.2)
1996 80.4  13.2 ( 20.9,  5.4) 100.0  5.2 ( 11.4, 1.0)
1997 78.0  15.6 ( 23.2,  8.0) 98.2  7.0 ( 13.1,  0.9))
1998 92.1  13.1 ( 19.0,  7.1)
1999 97.8  7.4 ( 13.4,  1.3)
2000 89.7  15.5 ( 21.4,  9.7)
2001 85.3  19.9 ( 26.6,  14.2)
aOtto et al (2003).
Decreased rates of advanced breast cancer
J Fracheboud et al
866
British Journal of Cancer (2004) 91(5), 861–867 & 2004 Cancer Research UK
C
l
i
n
i
c
a
laged 55–74 started to decline significantly from 1997 onwards
(Otto et al, 2003). After recalculation of the incidence rates for the
same age band, we found a significant reduction of advanced
diseases already in 1995, preceding the breast cancer mortality
reduction of a similar extent by 2 years (Table 3).
CONCLUSION
Breast cancer screening led to a temporary strong increase in the
breast cancer incidence, in particular of in situ carcinomas and
small lymph node negative invasive cancers in women aged 50–69
years. In this age category, the incidence rate of large tumours with
lymph node or distant metastases (T2þNþ/M1) decreased
significantly and was 12.1% lower in 1997 than before the start
of the screening programme. This reduction in advanced disease
precedes the observed significant breast cancer mortality reduc-
tion of a comparable extent by approximately 2 years. The
outcomes of our study confirm that population-based mammo-
graphy screening contributes to a reduction of advanced breast
cancer rates and breast cancer mortality.
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